BioSpace News Archive

Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies being presented at the American Academy of Neurology (AAN) 2022 Annual Meeting.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to two new employees to purchase an aggregate of 195,000 shares of common stock.

Atara Biotherapeutics, Inc. today announced FUJIFILM Diosynth Biotechnologies has completed the acquisition of Atara’s cell therapy manufacturing facility in Thousand Oaks.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 435,750 shares of its common stock and the grant of 240,900 restricted stock units to nine new employees.

NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation, announced positive, long-term safety and tolerability data for ND0612 at the American Academy of Neurology Annual Meeting (in Seattle, April 2-7, and virtually, April 24-27).

Enteris BioPharma, Inc. announced that CEO, Rajiv Khosla, Ph.D., was featured in Drug Development and Delivery discussing the ability of Enteris’ Peptelligence® and ProPerma® technologies to overcome the permeability and solubility issues that prevent the oral delivery of many “beyond the rule of 5" compounds, including peptides, peptidomimetics, and intermediate-sized small molecule compounds.

Precigen, Inc. today announced that the FDA has granted Fast Track designation for PRGN-3006 UltraCAR-T® in patients with relapsed or refractory (r/r) AML (clinical trial identifier: NCT03927261). PRGN-3006 was previously granted FDA Orphan Drug Designation.

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin its Revitalize-2 pivotal study.

Scorpion Therapeutics, Inc. today announced the appointment of Saurabh Saha, M.D., Ph.D. to its Board of Directors.

Genocea Biosciences, Inc. today announced details for a planned investor webinar to coincide with the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13.